A carregar...
Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
The incidence of renal‐related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active‐ and placebo‐controlled trials (N = 5598) and in a 104‐week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non‐c...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5485046/ https://ncbi.nlm.nih.gov/pubmed/28083972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12876 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|